133 related articles for article (PubMed ID: 23571802)
1. [PREFERE - the German prostatic cancer study: questions and claims surrounding study initiation in January 2013].
Wiegel T; Albers P; Bussar-Maatz R; Gottberg A; Härter M; Kieser M; Kristiansen G; Nettekoven G; Martus P; Schmidberger H; Wellek S; Stöckle M
Urologe A; 2013 Apr; 52(4):576-9. PubMed ID: 23571802
[TBL] [Abstract][Full Text] [Related]
2. [PREFERE--the German prostatic cancer study].
Porzsolt F
Urologe A; 2014 Mar; 53(3):388-9. PubMed ID: 23975217
[No Abstract] [Full Text] [Related]
3. [PREFERE--the German prostatic cancer study].
Weißbach L; Theuerkauf O
Urologe A; 2014 Mar; 53(3):387. PubMed ID: 23975216
[No Abstract] [Full Text] [Related]
4. [PREFERE--open questions].
Schäfer C; Weißbach L
Urologe A; 2014 Mar; 53(3):384-6. PubMed ID: 24510130
[No Abstract] [Full Text] [Related]
5. [Development of patient education materials for the "German Prostate Cancer Trial PREFERE"].
Sänger S; Wiegel T; Stöckle M; Härter M; Bergelt C
Z Evid Fortbild Qual Gesundhwes; 2015; 109(1):28-39. PubMed ID: 25839363
[TBL] [Abstract][Full Text] [Related]
6. Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients.
Putora PM; Engeler D; Haile SR; Graf N; Buchauer K; Schmid HP; Plasswilm L
Strahlenther Onkol; 2016 Mar; 192(3):182-9. PubMed ID: 26713323
[TBL] [Abstract][Full Text] [Related]
7. [Clarification regarding criticism on PREFERE].
Stöckle M
Urologe A; 2015 Dec; 54(12):1792-4. PubMed ID: 26704281
[No Abstract] [Full Text] [Related]
8. [Comparison of four treatment options for low-risk prostate cancer: Preference-based randomized study for the evaluation of four treatment modalities in prostate cancer with low or "early intermediate" risk (PREFERE) - trial AP 65/11 of the AUO].
Rexer H; Bussar-Maatz R
Urologe A; 2015 May; 54(5):723-5. PubMed ID: 25802104
[No Abstract] [Full Text] [Related]
9. Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
Wiegel T; Albers P; Bartkowiak D; Bussar-Maatz R; Härter M; Kristiansen G; Martus P; Wellek S; Schmidberger H; Grozinger K; Renner P; Schneider F; Burmester M; Stöckle M
J Cancer Res Clin Oncol; 2021 Jan; 147(1):235-242. PubMed ID: 32886212
[TBL] [Abstract][Full Text] [Related]
10. [Localised prostate cancer: the PREFERE trial].
Stöckle M; Bussar-Maatz R
Z Evid Fortbild Qual Gesundhwes; 2012; 106(5):333-5; discussion 335. PubMed ID: 22818151
[TBL] [Abstract][Full Text] [Related]
11. [PREFERE - Study on the rise].
Ohlmann CH; Stöckle M; Albers P; Schmidberger H; Härter M; Kristiansen G; Martus P; Wellek S; Bussar-Maatz R; Wiegel T
Urologe A; 2016 Mar; 55(3):313-7. PubMed ID: 26908120
[TBL] [Abstract][Full Text] [Related]
12. [The importance of pathology in the German prostate cancer study PREFERE].
Kristiansen G; Stöckle M; Albers P; Schmidberger H; Martus P; Wellek S; Härter M; Bussar-Maatz R; Wiegel T
Pathologe; 2013 Sep; 34(5):449-62. PubMed ID: 23963533
[TBL] [Abstract][Full Text] [Related]
13. Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey.
Hall JD; Boyd JC; Lippert MC; Theodorescu D
Urology; 2003 Feb; 61(2):402-7. PubMed ID: 12597956
[TBL] [Abstract][Full Text] [Related]
14. Variation in prostate cancer management.
Burki TK
Lancet Oncol; 2014 Sep; 15(10):e419. PubMed ID: 25328941
[No Abstract] [Full Text] [Related]
15. Two-step transurethral surgery of the prostate and permanent implant brachytherapy for patients with lower urinary tract symptoms and low- to intermediate-risk prostate cancer.
Ivanowicz AN; Wakeman CM; Hubbard RT; DeVoe WB; Haake MR; Teigland CM
Brachytherapy; 2012; 11(6):483-8. PubMed ID: 21937283
[TBL] [Abstract][Full Text] [Related]
16. [Radiotherapy vs. radical surgery].
Breul J; Wiegel T
Urologe A; 2016 Mar; 55(3):311-2. PubMed ID: 26940335
[No Abstract] [Full Text] [Related]
17. United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by region.
McNaughton Collins M; Barry MJ; Zietman A; Albertsen PC; Talcott JA; Walker Corkery E; Elliott DB; Fowler FJ
Urology; 2002 Oct; 60(4):628-33. PubMed ID: 12385923
[TBL] [Abstract][Full Text] [Related]
18. Implementation of an image guided intensity-modulated protocol for post-prostatectomy radiotherapy: planning data and acute toxicity outcomes.
Chua B; Min M; Wood M; Edwards S; Hoffmann M; Greenham S; Kovendy A; McKay MJ; Shakespeare TP
J Med Imaging Radiat Oncol; 2013 Aug; 57(4):482-9. PubMed ID: 23870349
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life using intensity-modulated radiation therapy for post-prostatectomy radiotherapy.
van Gysen KL; Kneebone AB; Guo L; Vaux KJ; Lazzaro EM; Eade TN
J Med Imaging Radiat Oncol; 2013 Feb; 57(1):89-96. PubMed ID: 23374560
[TBL] [Abstract][Full Text] [Related]
20. [Radiotherapy versus radiotherapy plus hormone therapy in the case of isolated PSA increase after radical prostatectomy. A prospective multicenter Phase III study of the AUO (AP 26/99) and the ARO (00/01)].
Schwarz R; Rexer H
Urologe A; 2004 Feb; 43(2):194-6. PubMed ID: 14991123
[No Abstract] [Full Text] [Related]
[Next] [New Search]